Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro

Uehara,Takashi; Mitsuhashi,Akira; Tsuruoka,Nobuhide; Shozu,Makio

doi:10.3892/or.2014.3611

Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro

Authors:
- Takashi Uehara
- Akira Mitsuhashi
- Nobuhide Tsuruoka
- Makio Shozu
View Affiliations

Affiliations: Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba 260-8670, Japan
Published online on: November 21, 2014 https://doi.org/10.3892/or.2014.3611
Pages: 744-750

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metformin is a diabetes drug with anticancer properties. Several studies have investigated the effects of metformin combined with chemotherapeutic agents, with controversial results. This study evaluated the efficacy of combined metformin/cisplatin treatment in an endometrial cancer cell line. Ishikawa cells were treated with metformin, cisplatin or both types of treatment. Cell proliferation was evaluated by quantification and colorimetric and thymidine incorporation assays, cell cycle progression was assessed by flow cytometry, and apoptosis by the caspase-3 activity assay. The effects of metformin and cisplatin used in combination were assessed under normoxic (21% O2) and hypoxic (1% O2) conditions. Mitochondrial morphology was examined using the MitoTracker dye, while function was assayed by lactate production. Discrepant results were obtained from the different assays of cell proliferation, with the value obtained from the colorimetric assay being higher than that from cell counts after drug treatment. Combined treatment with metformin (≥2 mM) and cisplatin (1 µM) had additive anti-proliferative effects on cells under normoxic conditions. However, the additive effect of metformin was attenuated under hypoxia. Metformin caused morphological and functional changes in mitochondria, which appeared shortened after exposure to metformin, while the connections between individual mitochondria appeared weaker. Additionally, decreased MitoTracker staining was observed after an 8-h exposure to metformin. The colorimetric assay did not accurately determine the effects of metformin and cisplatin on cell proliferation. The additive effects of metformin on cisplatin-induced inhibition of cell proliferation were attenuated under hypoxic conditions, while metformin compromised mitochondrial structure and function. Additional studies are needed to determine the efficacy of this drug combination in vivo.

View Figures

View References

1	Evans JM, Donnelly LA, Emslie-Smith AM, et al: Metformin and reduced risk of cancer in diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
2	Decensi A, Puntoni M, Goodwin P, et al: Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar
3	Noto H, Goto A, Tsujimoto T and Noda M: Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 7:e334112012. View Article : Google Scholar : PubMed/NCBI
4	Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA: Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 9:1057–1064. 2010. View Article : Google Scholar : PubMed/NCBI
5	Quinn BJ, Kitagawa H, Memmott RM, et al: Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab. 24:469–480. 2013. View Article : Google Scholar : PubMed/NCBI
6	Hanna RK, Zhou C, Malloy KM, et al: Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol. 125:458–469. 2012. View Article : Google Scholar : PubMed/NCBI
7	Dong L, Zhou Q, Zhang Z, et al: Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. J Obstet Gynaecol Res. 38:1077–1085. 2012. View Article : Google Scholar : PubMed/NCBI
8	Shank JJ, Yang K, Ghannam J, et al: Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol. 127:390–397. 2012. View Article : Google Scholar : PubMed/NCBI
9	Liu H, Scholz C, Zang C, et al: Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 32:1627–1637. 2012.PubMed/NCBI
10	Ashinuma H, Takiguchi Y, Kitazono S, et al: Antiproliferative action of metformin in human lung cancer cell lines. Oncol Rep. 28:8–14. 2012.PubMed/NCBI
11	Rattan R, Graham RP, Maguire JL, et al: Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 13:483–491. 2011.PubMed/NCBI
12	Kim HG, Hien TT, Han EH, et al: Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol. 162:1096–1108. 2011. View Article : Google Scholar :
13	Rocha GZ, Dias MM, Ropelle ER, et al: Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
14	Nilsson S, Huelsenbeck J and Fritz G: Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells. Cancer Lett. 304:60–69. 2011. View Article : Google Scholar : PubMed/NCBI
15	Iliopoulos D, Hirsch HA and Struhl K: Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 71:3196–3201. 2011. View Article : Google Scholar : PubMed/NCBI
16	Janjetovic K, Vucicevic L, Misirkic M, et al: Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol. 651:41–50. 2011. View Article : Google Scholar
17	Yasmeen A, Beauchamp MC, Piura E, et al: Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol. 121:492–498. 2011. View Article : Google Scholar : PubMed/NCBI
18	Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, et al: AMPK-mediated autophagy inhibits apoptosis in cisplatintreated tumour cells. J Cell Mol Med. 13:3644–3654. 2009. View Article : Google Scholar
19	Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
20	Gotlieb WH, Saumet J, Beauchamp MC, et al: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 110:246–250. 2008. View Article : Google Scholar : PubMed/NCBI
21	Graham GG, Punt J, Arora M, et al: Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 50:81–98. 2011. View Article : Google Scholar : PubMed/NCBI
22	Lalau JD, Lacroix C, Compagnon P, et al: Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care. 18:779–784. 1995. View Article : Google Scholar : PubMed/NCBI
23	Martin MJ, Hayward R, Viros A and Marais R: Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2:344–355. 2012. View Article : Google Scholar : PubMed/NCBI
24	Berridge MV, Herst PM and Tan AS: Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev. 11:127–152. 2005. View Article : Google Scholar : PubMed/NCBI
25	Ishiyama M, Miyazono Y, Sasamoto K, et al: A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta. 44:1299–1305. 1997. View Article : Google Scholar : PubMed/NCBI
26	Collier AC and Pritsos CA: The mitochondrial uncoupler dicumarol disrupts the MTT assay. Biochem Pharmacol. 66:281–287. 2003. View Article : Google Scholar : PubMed/NCBI
27	Pagliacci MC, Spinozzi F, Migliorati G, et al: Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival. Eur J Cancer. 29A:1573–1577. 1993. View Article : Google Scholar : PubMed/NCBI
28	Burzawa JK, Schmeler KM, Soliman PT, et al: Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol. 204:355.e1–7. 2011. View Article : Google Scholar
29	Soliman PT, Wu D, Tortolero-Luna G, et al: Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 106:2376–2381. 2006. View Article : Google Scholar : PubMed/NCBI
30	Mu N, Zhu Y, Wang Y, et al: Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol. 125:751–757. 2012. View Article : Google Scholar : PubMed/NCBI
31	Johnson N, Bryant A, Miles T, et al: Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev. 10:CD0031752011.PubMed/NCBI
32	Vale CL, Tierney J, Bull SJ and Symonds PR: Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev. 8:CD0039152012.PubMed/NCBI
33	El-Mir MY, Nogueira V, Fontaine E, et al: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 275:223–228. 2000. View Article : Google Scholar : PubMed/NCBI
34	Owen MR, Doran E and Halestrap AP: Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 348:607–614. 2000. View Article : Google Scholar : PubMed/NCBI
35	Wilcock C and Bailey CJ: Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 24:49–57. 1994. View Article : Google Scholar : PubMed/NCBI
36	Cantrell LF, Nelson CL, Gary RD and McIntyre IM: Fatal metformin intoxication with markedly elevated blood and liver concentrations. J Anal Toxicol. 36:657–659. 2012. View Article : Google Scholar : PubMed/NCBI
37	Sanchez-Alvarez R, Martinez-Outschoorn UE, Lamb R, et al: Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin. Cell Cycle. 12:172–182. 2013. View Article : Google Scholar :
38	Poot M, Zhang YZ, Krämer JA, et al: Analysis of mitochondrial morphology and function with novel fixable fluorescent stains. J Histochem Cytochem. 44:1363–1372. 1996. View Article : Google Scholar : PubMed/NCBI
39	Renehan AG, Tyson M, Egger M, et al: Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 371:569–578. 2008. View Article : Google Scholar : PubMed/NCBI
40	Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
41	Goodwin PJ, Pritchard KI, Ennis M, et al: Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 8:501–505. 2008. View Article : Google Scholar : PubMed/NCBI